Drugs / AZD9773
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01145560 | Oct 2010 → May 2012 | infectious disease with sepsis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01144624 | Jul 2010 → Aug 2011 | infectious disease with sepsis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00615017 | Jan 2008 → Jul 2009 | infectious disease with sepsis | AstraZeneca | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-10-25 | AstraZeneca | AstraZeneca initiates phase IIB study for AZD9773 (CytoFab) as a treatment for severe sepsis astrazeneca.com ↗ |
| 2010-10-25 | Orphan Australia | BTG plc: AstraZeneca initiates Phase IIb study for AZD9773 (CytoFab™) as a treatment for severe sepsis serb.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD9773 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00615017 ↗ |
| Action | Inhibit | “the reduction of measurable serum TNF-α by AZD9773” PMID 23001587 ↗ Sep 2012 |
| Modality | Protein / enzyme biologic | “AZD9773 is an ovine-derived, polyclonal, anti-tumour necrosis factor-alpha (TNF-α) antibody fragment.” PMID 23001587 ↗ Sep 2012 |
| Route | Intravenous | “single and multiple intravenous (i.v.) infusions of two doses of AZD9773” PMID 23681364 ↗ May 2013 |
| Target | TNF | “the reduction of measurable serum TNF-α by AZD9773” PMID 23001587 ↗ Sep 2012 |